SCH 563705 is primarily investigated for its potential therapeutic applications in the treatment of chronic inflammatory diseases. It has shown promise as a selective antagonist targeting specific receptors involved in inflammatory pathways, making it a candidate for conditions like rheumatoid arthritis and inflammatory bowel disease. Research suggests it may help modulate immune responses, reducing inflammation and associated tissue damage. Its development is focused on oral bioavailability, aiming to provide an effective and convenient treatment option for patients. Ongoing studies are exploring its efficacy and safety profile in clinical settings.